The low intestinal and hepatic toxicity of hydrolyzed fumonisin B1 correlates with its inability to alter the metabolism of sphingolipids by Grenier, Bertrand et al.
	
	

		
		
	

 
 
 !


" 
#
#$$!"!$
%&#''()
	

#
*+,,	+"-	
.+/"
 
+0
0+"1
	
.+*2"0+11+3"&
+% -	
	

			 

		
			
		 
		
		4)(4,	
	-
	5+
!678()!!(9:'"(9;7!%<))):"4='4
				5
	
 

#">"!!
The low intestinal and hepatic toxicity of hydrolyzed fumonisin B1 correlates
with its inability to alter the metabolism of sphingolipids
Bertrand Grenier a,c, Ana-Paula F.L. Bracarense b, Heidi Elisabeth Schwartz d, Catherine Trumel e,
Anne-Marie Cossalter a, Gerd Schatzmayr c, Martine Kolf-Clauw a,e, Wulf-Dieter Moll c,
Isabelle P. Oswald a,*
a INRA, UMR 1331 ToxAlim, Immuno-Myco-Toxicology team, 180 chemin de Tournefeuille BP 93173, 31027 Toulouse Cedex 3, France
bUniversidade Estadual de Londrina, Lab. Patologia Animal, Londrina, Brazil
cBIOMIN Research Center, Technopark 1, Tulln, Austria
dChristian Doppler Laboratory for Mycotoxin Metabolism, University of Natural Resources and Life Sciences, Vienna, Department IFA Tulln, Tulln, Austria
eUniversite´ de Toulouse, Ecole Nationale Ve´te´rinaire, Toulouse, France
1. Introduction
Mycotoxins are structurally low-molecular-weight metabolites
produced by fungi. As secondary metabolites they are not essential
to fungi growth but may contaminate animal feed and human food
at all stages of the food chain. Their worldwide occurrence is
considered to be a major risk factor affecting human and animal
health, and in addition leads to considerable worldwide economic
losses.
Among mycotoxins, fumonisins are of major concern. These
metabolites produced by Fusarium verticillioides and other fungi
are common fungal contaminants of corn and some other grains
[1]. Indeed, as much as 59% of corn and corn-based products are
contaminated worldwide with variable amounts of fumonisin B1
(FB1). Fumonisin B2 (FB2) and B3 (FB3) are simultaneously produced
with FB1 on grains, and the difference from FB1 is related to the
absence of hydroxyl group in FB2 and FB3 on the aminopentol
backbone. However, FB1 remains the most prevalent of the
fumonisin subspecies, about 70–80% of the total fumonisins
content [2]. Fumonisins exert complex biological effects. The toxic
effects of fumonisins range from hepatotoxicity and renal toxicity
to species-specific effects such as pulmonary edema in pigs and
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Fumonisins are mycotoxins frequently found as natural contaminants in maize, where they are produced
by the plant pathogen Fusarium verticillioides. They are toxic to animals and exert their effects through
mechanisms involving disruption of sphingolipid metabolism. Fumonisin B1 (FB1) is the predominant
fumonisin in this family. FB1 is converted to its hydrolyzed analogs HFB1, by alkaline cooking
(nixtamalization) or through enzymatic degradation. The toxicity of HFB1 is poorly documented especially
at the intestinal level. The objectives of this study were to compare the toxicity of HFB1and FB1and to assess
the ability of these toxins to disrupt sphingolipids biosynthesis. HFB1was obtained by a deesterification of
FB1with a carboxylesterase. Piglets, animals highly sensitive to FB1, were exposed by gavage for 2 weeks to
2.8 mmol FB1 or HFB1/kg body weight/day. FB1 induced hepatotoxicity as indicated by the lesion score, the
level of several biochemical analytes and the expression of inflammatory cytokines. Similarly, FB1 impaired
the morphology of the different segments of the small intestine, reduced villi height and modified intestinal
cytokine expression. By contrast, HFB1 did not trigger hepatotoxicity, did not impair intestinal morphology
and slightly modified the intestinal immune response. This low toxicity of HFB1 correlates with a weak
alteration of the sphinganine/sphingosine ratio in the liver and in the plasma. Taken together, these data
demonstrate that HFB1 does not cause intestinal or hepatic toxicity in the sensitive pig model and only
slightly disrupts sphingolipids metabolism. This finding suggests that conversion to HFB1 could be a good
strategy to reduce FB1 exposure.
Abbreviations: AP1, aminopentol; b.w., body weight; CerS, ceramide Synthase; FB1
FB2 FB3, fumonisin B1 B2 B3; GGT, Gamma-glutamyl transferase; HE, hematoxylin-
eosin; HFB1 HFB2 HFB3, hydrolyzed fumonisin B1 B2 B3; HPLC-FLD, high
performance liquid chromatography with postcolumn fluorescence derivatization;
IFN, interferon; IL, interleukin; IPEC-1, intestinal porcine epithelial cell line; LC–MS,
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sphingosine; TCA, tricarballylic acids; TNF, tumor necrosis factor.
* Corresponding author. Tel.: +33 561285480.
E-mail address: isabelle.oswald@toulouse.inra.fr (I.P. Oswald).
leukoencephalomalacia in horses [3,4]. In humans, exposure to
fumonisins has been linked to esophageal cancer and neural tube
defects [4,5]. The effect on the intestine has been less investigated
but villous alterations, reduced expression of immune mediators
and an increase in intestinal colonization by opportunistic
pathogenic bacteria in piglets have been detected [6–8].
Fumonisins are structurally similar to sphingoid bases, and
were identified as potent inhibitors of sphinganine N-acyl
transferase (ceramide synthase) [9]. Toxicity and carcinogenicity
of fumonisins are related to the disruption of sphingolipid
metabolism that occurs as a result of inhibition of ceramide
synthase [4,9].
Several strategies have been developed to reduce fumonisin
exposure. The alkali treatment of FB1-contaminated maize, named
nixtamalization, is widely used in Latin America, to produce
tortillas [10]. This alkaline hydrolysis cleaves the tricarballylic acid
side chains of FB1 leading to the formation of hydrolyzed fumonisin
B1 (HFB1). Conversion of FB1 to HFB1 can also be obtained by
microbial degradation, through the use of fumonisin carboxyles-
terases, an enzyme specific of the FB1 catabolism [11,12].
Carboxylesterases are ubiquitous enzymes, which can be found
in tissues of all animals, and are responsible for detoxification of
numerous exogenous compounds. However, so far it has not been
demonstrated inside of animals a degradation of FB1 through these
enzymes.
Toxicity of HFB1 is poorly documented. In vitro and in vivo data
indicate that HFB1 has a limited ability to inhibit ceramide
synthase [13–15]. Hepatic and renal lesions were reported in rats
fed nixtamalized material containing HFB1 [16,17]. By contrast, in
mice fed purified HFB1, no hepatotoxicity or pathological changes
were detected [14]. Similarly, HFB1 was not carcinogenic in rats
[18] and did not affect fetal development through the formation of
neural tube defects in either mice or rats, whether intraperitoneal-
ly or orally administered [15,19]. Thus, conflicting data exist on the
toxicity of HFB1.
Pig is highly sensitive to FB1 and, upon short term exposure,
adverse effects are observed in this animal species at lower levels
than in rodents [8,20,21]. Pig is potentially exposed to high level of
FB1. In addition pig can be regarded as the most relevant animal
model for extrapolating to humans, with a digestive physiology
very similar to that of human [22,23].
The objectives of this study were to compare the toxicity of
HFB1 and FB1 and to assess the ability of these toxins to disrupt
sphingolipid biosynthesis using the sensitive pig model [8,21].
HFB1 did not induce intestinal and hepatic toxicity at a dose level
that was significantly higher than the reported NOAEL for FB1 [19].
HFB1 slightly disrupted sphingolipid metabolism, although much
less potently than FB1. Together, the findings indicate that HFB1 is
less toxic than FB1, and that conversion of FB1 to HFB1 could be a
good strategy to reduce fumonisin exposure.
2. Material and methods
2.1. Animals
Eighteen, 4-week-old weaned female piglets (Pietrain/Duroc/
Large-white) were obtained locally in France. Animals were
acclimatized for 1 week in the animal facility of the INRA ToxAlim
Unit (Toulouse, France), prior to being used in experimental
protocols. Six pigs were allocated to each treatment on the basis of
body weight; control group: 10.98  0.16; FB1 group: 10.92  0.51;
HFB1 group: 10.98  0.46. During the 14-day experimental period,
animals were given free access to water and were fed with a basal diet
ad libitum, as previously described [21]. All animal experimentation
procedures were carried out in accordance with the European
Guidelines for the Care and Use of Animals for Research Purposes
(Directive 86/609/EEC). Three of the authors have an official
agreement from the French Veterinary Services for animal experi-
mentation.
2.2. Mycotoxins
Lyophilized culture material of F. verticillioides, containing
13.7 g/kg FB1, 5.2 g/kg FB2, and 1.7 g/kg FB3, was obtained from
Biopure – Romer Labs Diagnostic GmbH, Tulln, Austria. Aliquots of
24.25 g culture material were resuspended in 250 mL 10 mM
sodium phosphate buffer pH 7.0, homogenized with an ultra-
turrax, incubated at 22 8C for 30 min, and centrifuged for 10 min at
8000 rpm in a Beckman JA10 rotor. This extraction was repeated
twice. The supernatants from all three extractions of all aliquots
were combined, the pH was re-adjusted to 7.0, and this extract was
separated into two equal halves in 5 L bottles. Fumonisin
carboxylesterase FumD was prepared by fermentation of recom-
binant Pichia pastoris as previously described [11]. Lyophilized
fermentation supernatant was dissolved in water at a concentra-
tion of 100 mg/mL, and 774 mL of this solution was added per liter
to one of the two aliquots of extract. Both aliquots were incubated
overnight at 22 8C with shaking at 60 rpm, and both were heat-
inactivated by boiling in a microwave oven for one minute in
aliquots of about 650 mL. A portion of the FumD solution was heat-
inactivated for 40 min in a boiling water bath, and the same
amount of enzyme that was used for preparation of the hydrolyzed
fumonisin extract was added, in heat-inactivated form, to the
intact fumonisin extract. Samples of both extracts from before,
during, and after incubation were analyzed by LC–MS using a
previously described method [11] to confirm that the fumonisins
were hydrolyzed and intact, respectively, in the two extracts. Since
more material was required, the extracts were combined with
equal amounts of extracts which were prepared from the same
culture material in the same way, except that water instead of
10 mM phosphate buffer was used for extraction. The final extract
of intact fumonisins was analyzed by Quantas – Romer Labs
Diagnostic GmbH, Tulln, Austria, using a certified LC–MS method,
and found to contain 530.85 mg/L FB1, 133.30 mg/L FB2, and
35.60 mg/L FB3. Extracts were stored at 20 8C. For the no
fumonisins control group, 5 mM sodium phosphate containing
the same concentration of heat-inactivated FumD as the two
extracts was made.
2.3. Experimental design and tissue/blood sampling
Animals received daily by gavage the different solutions
(control, FB1, HFB1) at the concentration of 2.8 mmol FB1/kg
b.w./day. At weekly time intervals, blood samples were aseptically
collected from the left jugular vein. Blood was collected in tubes
containing sodium heparin for biochemistry, or citrate for
fibrinogen measurement (Vacutainer1, Becton-Dickinson, USA).
Plasma samples were obtained after centrifugation of blood and
stored at 20 8C for later analysis. Upon termination of the
experiment, corresponding to 14 days of dietary exposure to
treatments, immediately after electrical stunning, pigs were killed
by exsanguinations, and liver and the entire gastrointestinal tract
were removed. The mesentery was cut using scissors, and the small
intestine (SI) was aligned on a table and measured without
applying tension. The SI was divided into three parts of equal
length, and 15 cm tissue segments were collected from the middle
of each part (named in the present study as Proximal SI, Mid SI and
Distal SI). Subsamples of the SI segments were either fixed in 10%
buffered formalin (Sigma, Saint-Quentin Fallavier, France) for
histopathological analysis or flash-frozen in liquid nitrogen and
stored at 80 8C until RNA extraction. Liver and mesenteric nodes
were similarly prepared, and for liver an additional piece of hepatic
tissue (5–15 g for each animal) was kept at 80 8C until
sphingolipid analysis.
2.4. Biochemistry
Plasma concentrations of albumin, total proteins, cholesterol,
triglycerides, fibrinogen and activity of gamma-glutamyl transfer-
ase were determined by a Vitros 250 analyzer (Ortho Clinical
Diagnostics, Issy les Moulineaux, France) at the Veterinary School
of Toulouse (France).
2.5. Determination of sphinganine (Sa)/sphingosine (So) ratios
Assessment of sphingolipid metabolism, by measurement of
the content of sphingoid bases in plasma and liver samples, was
carried out according to Yoo et al. [24] with some modifications. In
short, 200 mL aliquots of plasma samples were spiked with C17-
sphingosine and C20-sphinganine (Avanti Polar Lipids, Alabama,
USA) as internal standards, 400 mL of chloroform (p.a., Merck,
Darmstadt, Germany) and 1.3 mL of methanolic potassium
hydroxide solution (0.154 M reagents from Merck) were added
and samples were shaken at 37 8C for 1 h. After further addition of
1.2 mL of chloroform, the chloroform phase was washed three
times with alkaline water (samples vortexed and centrifuged at
2500 rpm for 5–8 min between each washing) and subsequently
evaporated to dryness. The residues were derivatized using OPA
reagent (final volume 300 mL) according to Riley et al. [25] and the
resulting solutions were measured by HPLC-FLD. For analysis of
liver samples, aliquots of frozen liver samples were homogenized
on ice in the fourfold volume of cold phosphate buffer. Then,
100 mL aliquots of the homogenates were diluted with 100 mL of
water and worked up and analyzed in the same way as the plasma
samples.
For HPLC-FLD analysis, 25 mL of derivatized standards or
sample extracts were injected into the HPLC-system (Agilent 1100
series, Waldbronn, Germany) and separated on a C6 phenyl column
(50 mm  2 mm, 5 mm, Phenomenex, Aschaffenburg, Germany)
equipped with a pre-column of the same stationary phase at
0.5 mL/min using gradient elution. Mobile phase A and B consisted
of methanol (gradient grade for LC, Merck)/water/glacial acetic
acid (p.a., Merck) (A: 60:39.9:0.1, v/v/v; B: 90:9.9:0.1, v/v/v). The
following gradient was used: 0 min: 0% B, 4.5 min: 84% B, 6.8 min:
90%, 9 min: 90% B, 9.5 min: 100% B, 13.9 min: 100% B, 14 min: 0% B,
16 min: 0% B. Analytes were detected fluorimetrically (excitation
at 335 nm, emission at 440 nm). Concentrations of Sa and So were
determined on the basis of external calibration functions and the
Sa/So ratio was calculated for each animal in the biological
samples.
2.6. Determination of tissue lesions and villous morphometry
The tissue pieces were dehydrated through graded alcohols
and embedded in paraffin wax. Sections of 3 mm were stained
with hematoxylin-eosin (HE, Sigma) for histopathological
evaluation. Microscopic observations  in liver and in SI were
quantified as already described [21,26] with minor modifica-
tions (Table 1). A lesion score per animal was established by
taking into account the importance degree of the lesion (severity
factor) and its extent (intensity or observed frequency; scored
from 0 to 3). Morphometry was evaluated in the different
segments of intestine, by measuring the villi height randomly on
thirty villi using a MOTIC Image Plus 2.0 ML1 image analysis
system, as already described [26]. To evaluate lesions and
morphometry in these tissues, the slides were observed in a
blind way by the same pathologist, and irrespective of the
experimental groups.
2.7. Expression of mRNA encoding for cytokines by real-time PCR
Tissue RNA was processed in lysing matrix D tubes (MP
Biomedicals, Illkirch, France) containing guanidine-thiocyanate
acid phenol (Extract-All1, Eurobio, les Ulis, France) for use with the
FastPrep-24 (MP Biomedicals, Illkirch, France). Concentrations,
integrity and quality of RNA were determined spectrophotometri-
cally (O.D.260) using Nanodrop ND1000 (Labtech International,
Paris, France). The steps and conditions of reverse transcription
and real-time PCR were performed as previously described [21,26].
The sequences of the primers used in PCR are detailed in Table 2.
Primers were purchased from Invitrogen (Cergy Pontoise, France).
Amplification efficiency and initial fluorescence were determined
by DART-PCR method. Then, the values obtained were normalized
by both house-keeping genes b2-microglobulin and ribosomal
protein L32 (RPL32). Finally, gene expression was expressed
relative to the control group.
2.8. Statistical analysis
Following the Fisher test on equality of variances, one way
ANOVA using Statview software 5.0 (SAS Institute, Cary, NC, USA)
was used to analyze the differences between the different
treatment groups of animals at each time point. P values of 0.05
were considered significant.
3. Results
3.1. Comparative effects of FB1 and HFB1 on the liver
Ingestion of FB1 has been demonstrated to be hepatotoxic [3,4].
It was thus of interest to compare the effect of ingestion of FB1 and
HFB1 on the liver.
3.1.1. Histopathology
The lesions observed in the liver were mild to moderate for
all the animals. The main lesions observed in piglets treated
with FB1 were a nuclear vacuolization of hepatocytes, and
megalocytosis. One piglet also presented signs of necrosis. As
indicated by the lesion score, animals fed FB1 displayed
significant liver lesions when compared to control animal
(p < 0.001, Fig. 1). By contrast, the lesion score observed in
animals fed HFB1 was similar to the one observed in control
animals, indicating that HFB1 did not induce severe liver
damages.
Table 1
Establishment of a lesion score – endpoints used to evaluate histological lesions in
liver and in the small intestine.
Tissue Type of lesions (severity factor) Maximal score
Liver Disorganization of hepatic cords (1)
Hepatic cell vacuolization (1)
Inflammatory infiltrate (1) 21
Megalocytosis (2)
Necrosis (2)
Small intestine Lymphatic vessels dilation (1)
Interstitial edema (2)
Villi atrophy (2) 21
Villi fusion (2)
Notes: the score for each lesion was obtained by multiplying the severity factor by
the extent of the lesion. The organ score was then obtained by calculating the sum of
each lesion score. Severity factor (or degree of severity), 1 = mild lesions,
2 = moderate lesions; the extent of each lesion (intensity or observed frequency)
was evaluated and scored as 0 = no lesion, 1 = low extent, 2 = intermediate extent,
3 = large extent.
3.1.2. Biochemical analytes
Next, the effect of FB1 and HFB1 on plasmatic biochemical
analytes, as biomarkers of liver lesion and inflammation, was
compared. A time related increase in albumin, total protein
concentrations, cholesterol and triglycerides, fibrinogen and
gamma-glutamyl transferase (GGT) were observed in animals
treated with FB1 for 7 and 14 days (Table 3). Conversely, ingestion
of HFB1 for 7 or 14 days did not induce any change in the plasmatic
biochemical analytes (Table 3) when compared with the values
measured for control animals.
3.1.3. Cytokines expression
Liver also produces cytokines, with pro- or anti-inflammatory
properties. The comparative effect of the ingestion of FB1 and HFB1
on the expression of cytokine mRNA in the liver was analyzed and
described in Table 4. In FB1-treated animals, an increased liver
expression of IL-1b and IL-8 mRNA was observed when compared
to control animals (+55% and +82% respectively). The ingestion of
the toxin also significantly decreased the liver expression of IL-6,
IL-10, IL-18 and IFN-g (28%, 51%, 40% and 31% respectively,
when compared to control).
By contrast, 14 days of exposure to HFB1, had only a minor effect
on the liver expression of cytokines. Among the 6 cytokines
measured, HFB1 significantly modulated only the expression of IL-
6 (29% when compared to control group).
Taken together, these data indicate that ingestion of HFB1
induced minimal liver toxicity as measured by the liver lesion
(Fig. 1), blood biochemistry (Table 3) and liver cytokine expression
(Table 4).
3.2. Comparative effects of FB1 and HFB1 on the small intestine
The digestive tract is the first compartment exposed to
mycotoxins and several studies have demonstrated that the
intestine is a target for FB1 [27]. The effect of FB1 and HFB1 were
compared along the small intestine (SI).
3.2.1. Histopathology
As already observed in the liver, the intestinal lesions were mild
to moderate. Ingestion of FB1 induced lymphatic vessel dilation
and interstitial edema in the proximal-SI, as well as lymphatic
vessel dilation, villi atrophy and fusion, in both mid- and distal-SI.
Table 2
Nucleotide sequences of primers for real-time PCR.
Gene Primer concentration and sequence Amplicon size Genbank no. References
RPL32 F (300 nM) TGCTCTCAGACCCCTTGTGAAG 106 NM_001001636 [50]
R (300 nM) TTTCCGCCAGTTCCGCTTA
b2-microglobulin F (900 nM) TTCTACCTTCTGGTCCACACTGA 162 NM_213978 [28]
R (300 nM) TCATCCAACCCAGATGCA
IL-12p40 F (300 nM) GGTTTCAGACCCGACGAACTCT 112 NM_214013 [28]
R (900 nM) CATATGGCCACAATGGGAGATG
IL-8 F (300 nM) GCTCTCTGTGAGGCTGCAGTTC 79 NM_213867 [21]
R (900 nM) AAGGTGTGGAATGCGTATTTATGC
IL-1b F (300 nM) GAGCTGAAGGCTCTCCACCTC 87 NM_001005149 [28]
R (300 nM) ATCGCTGTCATCTCCTTGCAC
IL-6 F (300 nM) GGCAAAAGGGAAAGAATCCAG 87 NM_214399 [21]
R (300 nM) CGTTCTGTGACTGCAGCTTATCC
IFN-g F (300 nM) TGGTAGCTCTGGGAAACTGAATG 79 NM_213948 [51]
R (300 nM) GGCTTTGCGCTGGATCTG
TNF-a F (300 nM) ACTGCACTTCGAGGTTATCGG 118 NM_214022 [52]
R (300 nM) GGCGACGGGCTTATCTGA
IL-2 F (300 nM) GCCATTGCTGCTGGATTTAC 159 AY294018 [53]
R (300 nM) CCCTCCAGAGCTTTGAGTTC
IL-10 F (300 nM) GGCCCAGTGAAGAGTTTCTTTC 51 NM_214041 [26]
R (300 nM) CAACAAGTCGCCCATCTGGT
Fig. 1. Effects of FB1 and HFB1 treatments at day 14 on the liver. Pigs were orally exposed to FB1 ( ), HFB1 (&) or were kept as control animals (&). Liver of (A) a control pig, (B)
a HFB1 treated-pig and (C), (D) an FB1 treated-pig. (A) and (B) normal liver architecture, HE. 10. (C) Hepatocyte vacuolization (arrow) and megalocytosis (arrowhead), HE.
40. (D) focal necrosis (arrow). HE. 10. Lesion scores were established after histological examination according to the severity and the extent of the lesions. Values are
mean  SEM of 5 animals. Graphic bars without a common letter differ (P < 0.05).
In all sections of the small intestine, the lesion score observed in
FB1-treated animals was significantly higher than the one observed
in control animals (p < 0.05, p < 0.001, p < 0.05 in proximal, mid
and distal SI, respectively). Ingestion of HFB1 did not elicit
significant lesions in the small intestine, and the lesion scores
were not statistically different from the ones observed in control
animals (Fig. 2).
The morphology of the intestine was also evaluated by
measuring the villi height. As reported in Table 5, FB1 significantly
decreased the height of villi in the small intestine (20% and 31%
mid and distal SI, respectively). By contrast, ingestion of HFB1 had a
moderate, non-significant effect on this parameter (Table 5).
3.2.2. Cytokines expression
The digestive tract is also an immune organ and the ingestion of
FB1 is known to modulate the intestinal expression of cytokine
[6,28]. In the current study, we compared the effect of FB1 and HFB1
on the expression of cytokines in the different parts of the small
intestine and mesenteric lymph nodes.
As shown in Fig. 3, ingestion of FB1 decreased significantly the
expression of mRNA encoding for IL-1b, IL-10, IL-2 and IFN-g in the
proximal SI (59%, 43%, 41%, 46%, respectively), IL-1b, IL-6,
IL-2 and IFN-g in the mid SI (38%, 33%, 38%, 46%,
respectively), IL-1b and IL-8 in the distal SI (56%, 42%
respectively), and the levels of mRNA encoding for IL-1b, IL-8,
IL-6, TNF-a, IL-2, IFN-g and IL-12p40 in mesenteric nodes (51%,
59%, 14%, 27%, 24%, 29% and 45%, respectively).
Conversely, the profile of mRNA levels in the intestines from
HFB1-treated animals was only slightly altered when compared to
control animals. We only observed a significant alteration of IL-
12p40 in the mid- and distal SI (+91% and +54%, respectively), IFN-
g in the distal SI (+61%) as well as an alteration of TNF-a and IL-6
expression in the mesenteric lymph nodes (26% and 18%
respectively).
Taken together, these data indicate that when compared with
ingestion of FB1, ingestion of HFB1 was found to induce minimal
intestinal toxicity as measured by the histopathology (Fig. 2),
morphology (Table 5) and cytokine expression (Fig. 3).
3.3. Comparative effect of FB1 and HFB1 on sphingolipid metabolism
FB1 disrupts sphingolipid metabolism by inhibiting ceramide
synthases, leading to an increased sphinganine (Sa)/sphingosine
(So) ratio in tissues and body fluids [4]. Concentrations of Sa and So
were measured in plasma and liver samples from piglets belonging
to the three different experimental groups and the Sa/So ratios
were calculated. As expected, ingestion of FB1 induced an
accumulation of Sa and to a lesser extent of So both in plasma
and liver of piglets. As shown in Fig. 4, the Sa/So ratios of animals
treated with FB1 was 8–10 fold higher in plasma and 28 fold higher
in liver, when compared with control animals.
By contrast, ingestion of HFB1 did not affect the sphingolipid
metabolism in the plasma samples. In the liver, the Sa/So ratio was
two-fold higher in animals treated with HFB1when compared with
the control animals.
4. Discussion
The aim of the current study was to compare the in vivo toxicity
of FB1 and its fully hydrolyzed form, HFB1 (also named
aminopentol AP1). HFB1 is produced during nixtamalization, a
traditional corn treatment used in Mexico, Central America, as well
as in the United States, to make masa and tortillas [10]. This
alkaline hydrolysis process, using calcium hydroxide and heat,
removes the tricarballylic acid side chains from FB1. Processing of
contaminated foods/feeds by fumonisin carboxylesterase and/or
microorganisms expressing this enzyme may also lead to the
formation of HFB1 [11]. The data presented in this paper clearly
show that hydrolysis of FB1 strongly reduces its toxicity, both in
the liver and the gastrointestinal tract.
In the present study, piglets were exposed to 2.8 mmol FB1 or
HFB1/kg b.w./day for 14 days. This FB1 concentration allowed to
induce toxicity, and thus to compare at equimolar concentration
the HFB1 effects. Based on averaged feed consumption for pigs of
this age, this dose corresponds to feed contaminated with a
concentration of 37–44 mg of FB1/kg.
Over the 14 days exposure period, no effect on animal growth
was observed (data not shown). This is in agreement with earlier
studies where no effect on body weight gain was reported in pigs
fed 47 mg FB1/kg feed [29]. Signs of hepatotoxicity were observed
upon ingestion of FB1, and are in accordance with previous reports
[3,4]. In the present study, biochemical markers of hepatic and
Table 3
Effects of FB1 and HFB1 treatments on some biochemical values in plasma.
Biochemical parameters Animal treatments
Control FB1 HFB1
Albumin (g/L) Day 7 26.2  0.8a 31.3  0.7b 26.1  0.9a
Day 14 26.5  1.1a 31.6  1.0b 25.1  0.7a
Total proteins (g/L) Day 7 49.7  0.8a 58.7  1.4b 49.9  1.2a
Day 14 50.4  0.7a 61.4  1.2b 50.7  0.6a
Triglycerides (mmol/L) Day 7 0.89  0.12a 1.19  0.16a 0.76  0.11a
Day 14 0.82  0.17a 1.34  0.14b 0.82  0.09a
Cholesterol (mmol/L) Day 7 2.70  0.22a 3.78  0.21b 2.16  0.34a
Day 14 2.63  0.26a 4.44  0.30b 2.12  0.25a
Fibrinogen (g/L) Day 7 2.16  0.13a 2.91  0.21b 1.89  0.27a
Day 14 1.68  0.05a 2.96  0.12b 1.72  0.05a
GGT (U/L) Day 7 46.0  2.4a 71.2  6.2b 53.2  5.3a,b
Day 14 51.2  1.4a 146.2  32.3b 71.2  12.8a,b
Notes: GGT: g-glutamyl transferase. Results are expressed as mean  SEM of five animals. Means in a row without a common letter differ (P < 0.05).
Table 4
Effect of a 14-days exposure to FB1 and HFB1 on the mRNAs level of hepatic
cytokines.
Cytokines Animal treatments
Control FB1 HFB1
IL-1b 1.00  0.10a 1.55  0.20b 1.27  0.21a,b
IL-8 1.00  0.09a 1.82  0.55a 1.26  0.10a
IL-6 1.00  0.08a 0.72  0.08b 0.71  0.07b
IL-10 1.00  0.15a 0.49  0.06b 0.98  0.08a
IFN-g 1.00  0.11a 0.69  0.04b 1.00  0.25a,b
IL-18 1.00  0.01a 0.59  0.06b 0.86  0.05a
Notes: results are expressed in arbitrary units relative to the control group. Results
are mean  SEM of 5 animals. Means in a row without a common letter differ (P < 0.05).
renal lesions showed moderate increases, except GGT showing
higher increase. Although this toxin is able to target different
tissues or cells according to species, FB1 commonly acts on the liver
of both laboratory and farms animals, and affects structural
integrity and functions. Microscopic changes observed in the
present experiment were already described in the literature, and
included a disorganization of hepatic cords, hepatocellular
vacuolation, megalocytosis, apoptosis, necrosis and cell prolifera-
tion [3,4]. Similarly, biochemical changes were reported in pigs
after FB1 ingestion [29]. Analysis of the cytokines network upon
exposure to this mycotoxin is less documented. Nevertheless, an
increase of mRNA encoding for the pro-inflammatory mediators IL-
1b and IL-8 has already been observed in the liver or the lung of
treated animals [30,31]. Levels of IL-6 and IL-10, cytokines with
anti-inflammatory properties [32,33], were greatly reduced in liver
and could thereby confirm the inflammatory state in piglets
exposed to FB1 [34].
By contrast, hepatotoxicity was not observed in HFB1-treated
piglets, as measured by the liver lesion, blood biochemistry and
liver cytokine expression. Indeed, no microscopic lesion (mega-
locytosis, vacuolar degeneration) was noticed in those animals.
Similarly, biochemical analytes linked with protein and lipid
metabolism were not altered by the ingestion of HFB1. The
plasmatic concentrations of GGT and fibrinogen were also
unaffected following HFB1 exposure. These results confirm
previous observations including the absence of lesions and the
unmodified values of biochemical analytes in animals exposed to
purified HFB1 [4,15,35]. However, it should be mentioned that in
vitro, the hydrolysis products of FB1 and FB2, especially HFB2
exhibited a higher cytotoxic activity on primary rat hepatocytes
than their respective parent molecules [18]. In the present
experiment, the liver expression of cytokines was slightly
modulated in animals exposed to HFB1, but to a lesser extent
than in those from that FB1 group. To the best of our knowledge this
is the first report on the effect of HFB1 on cytokines in liver.
In this study, we also compared the intestinal toxicity of FB1 and
HFB1. The gastrointestinal tract is a primary site of mycotoxins
exposure, and following ingestion of contaminated food or feed,
intestinal epithelial cells could be exposed to a high concentration
of toxicants, potentially affecting intestinal functions [27]. FB1 was
proven to affect the intestine as shown by the in situ inhibition of
ceramide synthase [36,37]. This inhibition, could explain some
adverse effects reported, such as alteration of the proliferation and
the barrier function of intestinal cells [38]. In the present study, we
observed that the intestine of animals exposed to this mycotoxin
displayed mild to moderate tissular lesions including villi atrophy
and fusion. Occurrence of these lesions was high in the intestine of
animals exposed to FB1, especially in the second part of the small
intestine. These findings are in agreement with the villous fusion
and atrophy observed in the intestine of pigs treated with similar
doses of FB1 (30 ppm) [7] and in the intestine of chicks fed with 61–
546 ppm FB1 [39]. Effects of HFB1 on the intestine are poorly
documented. Most of the data concern the effect of this toxin on
intestinal cell lines to assess its effect on cell viability, HFB1
acylation or sphingoid bases content [35,40,41]. In the current
study, we observed that ingestion of HFB1 does not alter the
intestinal integrity, as assessed by the villi morphometry and the
lesion scores in different intestinal segments.
Fig. 2. Effects of FB1 and HFB1 treatments at day 14 on the small intestine (SI). Pigs were orally exposed to FB1 ( ), HFB1 (&) or were kept as control animals (&). Mid SI of (A)
control animals – continuous epithelium with normal villi, (B) FB1-treated animals – discontinuous epithelium with villi flattening and fusion, and (C) HFB1-treated animals –
weak villi flattening. HE. 10. Lesion scores were established after histological examination according to the severity and the extent of the lesions. Values are mean  SEM of 5
animals. Graphic bars without a common letter differ (P < 0.05).
Table 5
Effect of 14-days exposure to FB1 and HFB1 on the villi morphometry in the small
intestine.
Small intestine segment Animal treatments
Control FB1 HFB1
Proximal SI 300  16a 259  17a 255  19a
Mid SI 321  13a 259  21b 297  10a,b
Distal SI 265  13a 182  13b 241  7a
Notes: results are villi height in mm, they are expressed as mean  SEM for 5 animals.
Means in a row without a common letter differ (P < 0.05).
The intestine is also an immune site where immunoregulatory
mechanisms simultaneously defend against pathogens and pre-
serve tissue homeostasis to avoid immune-mediated pathology in
response to environmental challenges [42]. Few data are available
with regard to the effects of FB1 on the intestinal immunity, and
even lesser on cytokines production. FB1 decreases the expression
and the synthesis of IL-8 in the porcine epithelial intestinal cell
line, IPEC-1 and in the ileum of animals exposed to the toxin [6].
The FB1-induced IL-8 decrease may lead to a reduced recruitment
of inflammatory cells in the intestine during infection and may
participate in the observed increased susceptibility of exposed
piglets to intestinal infections [8,43]. FB1 exposure also leads to a
reduced intestinal expression of IL-12p40, an impaired function of
intestinal antigen presenting cells, with decreased upregulation of
major histocompatibility complex class II molecule (MHC-II) and
reduced T cell stimulatory capacity upon stimulation [28]. In the
present study, a decreased expression of most of the cytokines was
observed in the different part of the intestinal compartments
following FB1 ingestion. Indeed, an important decrease of the IL-
1b, IL-2, IFN-g and to a lesser extent IL-8 mRNAs was observed in
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Fig. 3. Effects of FB1 and HFB1 treatments at day 14 on the mRNA levels encoding cytokines in the intestine. Pigs were orally exposed to FB1 ( ), HFB1 (&) or were kept as
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Fig. 4. Effects of FB1 and HFB1 treatments on the sphinganine to sphingosine (Sa/So)
ratio in plasma and liver samples. Pigs were orally exposed to FB1 ( ), HFB1 (&) or
were kept as control animals (&). The Sa/So ratio was determined at days 0, 7 and
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animals. Graphic bars without a common letter differ (P < 0.05).
the upper intestinal tract and in the gut-associated lymphoid
tissue.
By contrast, the intestinal profile of cytokines after exposure
to HFB1 revealed minimal changes when compared with non-
exposed animals. These changes included a slight upregulation
of the expression of some cytokines in the mid and distal parts
of the SI, and a slight downregulation of TNF-a and IL-6 mRNAs
in the mesenteric nodes. In comparison to the changes induced
upon FB1 exposure, these HFB1 effects are very weak. This
suggests that animals consuming HFB1 would be able to drive a
correct immune response and to defend efficiently against
potential invaders. To our knowledge, this is the first study
investigating the effect of HFB1 on the intestinal morphology
and the immune response.
FB1 inhibits ceramide synthase, leading to an accumulation of
sphinganine and to a lesser extent of sphingosine. The Sa/So ratio
is a sensitive biomarker of FB1 toxicity and indicates the degree
of sphingolipid metabolism disruption [9,25]. This elevation in
sphinganine, a highly bioactive compound, initiates a cascade of
cellular alterations that are thought to be largely responsible for
the toxicity of FB1. To inhibit ceramide synthase, the amino-
pentol backbone of FB1 competes for binding of the sphingoid
base substrate, whereas the tricarballylic acids (TCA) side chains
interfere with binding of the fatty acid acyl-CoA [40,44]. Removal
of the TCA diminishes the potency of ceramide synthase
inhibition, and therefore the accumulation of sphingoid bases.
In the present work, we observed that ingestion of HFB1 did not
block ceramide synthase, which is in line with previous reports,
that the TCA moieties are required for maximal inhibition of the
enzyme [13–15,18,45]. Nevertheless, it should be mentioned
that HFB1 is not only an inhibitor but also a substrate for
acylation by ceramide synthase [35,40]. The absence of TCA
allows HFB1 to be acylated, and acylation was observed in the
presence of palmitoyl-CoA leading to the formation of N-
palmitoyl-AP1. This latter compound is highly cytotoxic for
HT29 cells, and a potent inhibitor of ceramide synthase [40].
Acylation was also evaluated in rats, and while formation of N-
acyl-AP1 occurs and produces metabolites with fatty acids of
various chain lengths, no toxicity was observed [35]. We cannot
exclude that acylation occurred in our experiment, however
neither increase in sphinganine concentrations nor toxicity were
detected. Nonetheless, this aspect warrants further investiga-
tions, considering that there are multiple isoforms of ceramide
synthase (CerS) showing different tissular expression and
difference in fatty acyl-CoA selectivity. Results may also vary
depending on animal species.
This paper demonstrates that ingestion of HFB1 results in
strongly reduced toxicity compared to ingestion of FB1. Absence of
reproductive and hepatic toxicity of HFB1 has already been
described in rats and in mice exposed to the toxin during feeding
trials or by intra-peritoneal injection [14,15,19]. The present study
expands this knowledge by adding that HFB1 does not induce toxic
effect in the intestine (lesion, inflammatory reaction) or inflam-
mation in the liver. Previous studies which suggested toxicity of
HFB1 [16,17,46] were performed with nixtamalized culture
material and it has been proposed that the toxic effects were
mediated by residual, partially hydrolyzed or ‘‘hidden’’ FB1 (matrix
bound forms not detected by HPLC) remaining in the nixtamalized
preparations [15,35,47–49]. The HFB1 used in this study was
obtained by enzymatic treatment of F. verticillioides culture
material with the fumonisin carboxylesterase FumD [11], and
complete hydrolysis, i.e., absence of partially hydrolyzed fumoni-
sins, was confirmed by LC–MS. Our results indicate that, HFB1 is
less toxic than FB1. Thus, enzymatic degradation of FB1, with
carboxylesterase, could be a good strategy to reduce fumonisin
exposure.
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